PURE Bioscience, Inc. (OTCMKTS:PURE) Sees Large Decrease in Short Interest

PURE Bioscience, Inc. (OTCMKTS:PURE) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 400 shares, a decrease of 97.2% from the November 15th total of 14,500 shares. Based on an average daily volume of 46,900 shares, the short-interest ratio is currently 0.0 days.

PURE Bioscience Stock Up 11.1 %

Shares of PURE Bioscience stock traded up $0.01 during mid-day trading on Friday, reaching $0.07. 52,615 shares of the stock traded hands, compared to its average volume of 29,677. The business has a 50-day moving average of $0.09 and a 200 day moving average of $0.08. The stock has a market capitalization of $7.83 million, a PE ratio of -1.75 and a beta of 0.01. PURE Bioscience has a fifty-two week low of $0.06 and a fifty-two week high of $0.16.

PURE Bioscience (OTCMKTS:PURE) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.01) EPS for the quarter. The company had revenue of $0.47 million during the quarter.

PURE Bioscience Company Profile

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.